Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NPS (NPSP) rode a rollercoaster last week, falling $1.45 (26%) on a slew of news. The company stumbled out of the gates on Monday,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury